CD86 Blocking Peptide for STJ500487 is synthetically produced from the 250-329 sequence and is suitable for use in western blot applications.
Applications
Immunodepletion/Immunocompetition
Note
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Product Properties
Formulation
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice.
Storage Instruction
Store at-20°C for long term storage. Avoid freeze-thaw cycles.
Synthetic peptide taken within amino acid region 250-329 on human CD86 protein.
Immunogen Region
250-329
Specificity
This blocking peptide is recommended for use in combination with CD86 antibody, STJ500487
Additional Info
Tissue Specificity
Expressed by activated B-lymphocytes and monocytes.
Post Translational Modifications
Polyubiquitinated.which is promoted by MARCH8 and results in endocytosis and lysosomal degradation.
Function
Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation. Also involved in the regulation of B cells function, plays a role in regulating the level of IgG(1) produced. Upon CD40 engagement, activates NF-kappa-B signaling pathway via phospholipase C and protein kinase C activation. Isoform 2: Interferes with the formation of CD86 clusters, and thus acts as a negative regulator of T-cell activation. (Microbial infection) Acts as a receptor for adenovirus subgroup B.
